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INTRODUCTION
Momordica charantia L. belongs to the cucurbitaceae 
family is a climbing plant found frequently covering 
fences and shrubs along the paths from north to 
south regions of Brazil, especially during the rainy 
season. It is a species native to Africa that was 
introduced to South America in the colonial period 
by black slaves from the African continent.1,2
Momordica charantia is found in nature in various 
forms distinguishable by the size of the fruits. Two 
of which are more frequent the northeastern Brazil, 
where it is popularly reffered to as the Melão-
de-Caetano, erva-de-lavadeira “laundry-plant”, 
because the whole plant is used in the washing of 
clothes in the rural areas. A variety of large fruits 
that can measure up to 30 cm in length and about 5 
cm in diameter is the most common variety in the 
Asian countries, used both in food and in medicinal 
preparations. This variety was introduced to Brazil 
in this century, and its fruits can readily be found 
in the open markets like in the state of São Paulo 
(Figures 1 and 2).3
In the state of Ceará, northeastern Brazil, one of 
the earliest records of M. charantia is found in the 
Coleção Descritiva das Plantas da Capitania do Ceará 
do Naturalista Feijó “Descriptive collection of Plants 
of Cearáregion” by João da Silva Feijó, who was a 
Ceará naturalist in 1818.4 As at that time, Brazil 
was still under Portuguese colonization. However, 
other works on northeastern Brazillian Flora by 
the naturalist Freire Allemão, who also recorded 
the species, were based on this collection.5 In the 
twentieth century, the ethnobotanical descriptions 
of M. charantia, including its use in the popular 
medicine of the northeast, can be encountered in 
important works like the Formulário Fitoterápico 
(Phytotherapeutic Formulary) of Professor Dias da 
Rocha,6 Plantas do Nordeste, especialmente do Ceará 
(Plants of the Northeast, especially of Ceará).7 and 
Plantas da Medicina Popular do Nordeste (Plants of 
the Northeastern People's Medicine).8
In the Brazilian state of Ceará, the plant is used 
topically in compresses, plasters, washes for the 
treatment of ulcers and various skin disorders 
ABSTRACT
Introduction: Momordica charanthia L., Curcubitaceae, is a pantropical food and medicinal plant. 
The plant is included in the Official List of Brazilian Medicinal Plants of interest to the Brazilian 
Unified Health System. The study aimed to perfom microbiological studies with extracts of 
Momordica charanthia L. including chemical characterization of the active extracts. Methods: 
The antimicrobial activity was evaluated with the hydroalcoholic and acetone extracts of M. 
charantia leaves, fruits and seeds from northeastern Brazil using microdilution broth technique 
on the selected clinical bacterial and fungal strains. Extracts that presented antimicrobial 
were subjected to ultra performance liquid chromatography-quadrupole time-of-flight mass 
spectrometry (UPLC-QToF-ESI-MS). Results: The in vitro antimicrobial assays demonstrated 
that the leaves extracts presented good antibacterial effect against four Staphylococcus 
aureus strains, and a weak antifungal activity agaist Candida albicans. Fourteen compounds 
were identified in the hydroalcoholic extract, while 12 were found in the acetone extract. The 
most important compounds were kaempferol, quercertin and triterpenoids like cucurbitacins. 
Conclussion: The present study demonstrated the potential antibacterial activity of M. charantia 
L. from northeastern part of Brazil, in addition to important phytochemical metabolites known 
to possess antibacterial activities, particularly against microrganisms of clinical importance. 
The UPLC phytochemical profile of the Brazilian variety is reported here for the first time. 
The phytochemical profile of the LHE and FAE demonstrated the presence of biologically and 
pharmacologically active compounds. There is lack of biological and pharmacological studies to 
support the medicinal uses of this important plant. The Brazilian variety of M. Charantia could 
be a potential therapeutic agent in the treatment of infections. 
Key words: Ethnopharmacology, in vitro activity, Antibacterial, Antifungal.
William Antonio Sagástegui 
Guarniz1,8, Kirley Marques Canuto2, 
Paulo Riceli Vasconcelos Ribeiro2, 
Hilania Valeria Dodou1, Karla 
Nascimento Magalhaes3, Kellen 
Miranda Sá3, Patrícia Georgina 
Garcia do Nascimento4, Karine 
Lima Silva5, Gleilton Weyne Passos 
Sales6, Mirian Parente Monteiro1, 
Nadia Accioly Pinto Nogueira1, 
Sikiru Olaitan Balogun7,*, Mary 
Anne Medeiros Bandeira1
1Department of Pharmacy, Faculty of 
Pharmacy, Odontology and Nursing, 
Universidade Federal do Ceará, Ceará, BRAZIL.
2Embrapa Agroindústria Tropical, Ceará, 
BRAZIL.
3Horto de Plantas Medicinais Prof FJA Matos, 
Universidade Federal do Ceará, BRAZIL.
4Department of Chemistry, Faculty of 
Chemistry, Universidade Federal do Ceará, 
Ceara, BRAZIL.
5Department of Medicine, Faculty of Medicine, 
Universidade Federal do Ceará, Ceará, BRAZIL.
6Departamento de Análises Clínicas e 
Toxicológicas, Universidade Federal do Ceará, 
Ceará, BRAZIL.
7Faculdade Noroeste do Mato Grosso - AJES, 
78.320-000, Juína, Mato Grosso, BRAZIL.
8Department of Pharmacology, Faculty 
of Pharmacy and Biochemistry, National 
University of Trujillo, PERU.
Correspondence
Sikiru Olaitan Balogun
Faculdade Noroeste do Mato Grosso - AJES, 
78.320-000, Juína, Mato Grosso, BRAZIL.
E-mail: balogun.zhikrullah@gmail.com
History
• Submission Date: 15-07-2019;
• Review completed: 14-08-2019;
• Accepted Date: 14-08-2019.
DOI : 10.5530/pj.2019.11.203
Article Available online 
http://www.phcogj.com/v11/i6
Copyright
© 2019 Phcogj.Com. This is an open- 
access article distributed under the terms 
of the Creative Commons Attribution 4.0 
International license.
1313Pharmacognosy Journal, Vol 11, Issue 6, Nov-Dec, 2019
Guarniz, et al.: Momordica Charantia L. Variety from Northeastern Brazil: Analysis of Antimicrobial Activity and Phytochemical Components
Figures 1 and 2: Photos of F. J. A. Matos: Momordica charantia L. variety.
(abscesses, boils, pediculosis, pruritus and burns). And recently, 
its ethnomedicinal uses from the same region was detailed in the 
Ethnopharmacopoeia of Professor Francisco José de Abreu Matos9 
which included wound healing, as antiseptic, treatments of gonorrhea, 
skin diseases, colitis, gynecological inflammation, external tumor, 
vaginal discharge, infected wounds and for weight loss. The plant parts 
used are theleaves (its juice, natural form or as poultice, decoction 
and maceration in water, fruit (natural form or as poultice, its branch 
and the whole plant). It is also prepared in form of tintures/alcohol 
extract and is employed externally to treat skin infections or parasite 
infestations.10,11
This plant has received a lot of attention due to its many 
ethnomedicinal and culinary uses. Biological and pharmacological 
studies of M. charantia have shown interesting therapeutic 
potentials, particularly its antidiabetic12-17, antileishmania18, anti-
HIV19, analgesics and anti-inflammatory activities.20 In addition, 
pharmacological and biological action of its various metabolites 
have been cited.21,22
Due to the ethnomedicinal importance of the local Brazilian variety, 
this species has been included in the National List of Medicinal 
Plants of Interest to Brazilian Public Health System23 and is also part 
of the Official List of Medicinal Plants of Ceará, a northeastern state 
of Brazil (REPLAME-CE).24 The plant also featured in the Brazilian 
Pharmacopoeia Phytotherapeutics Formulary.25Although, the 
antimicrobial properties of varieties other than that from Brazil have 
been cited in many studies using varying biological and pharmacological 
models, extracts from varying solvents26-28, few studies have been done 
on M. charantia antimicrobial activities collected in the northeastern 
region of Brazil.29,30 To the best of our knowledge, there is no detailed 
phytochemical studies of this important medicinal and food plant of 
thislocal variety from northeastern region of Brazil, despites being 
part of the Official Plant Lists. It is on this basis that we conducted 
the present study to establish scientific proof for its popular use in 
treating infections, to standardize extract with promising antibacterial 
activity and relate its metabolites content based on literature sources 
to it ethnomedicinal uses by people inhabiting northeastern region 
(Caatinga Biome) of Brazil. 
In this study, we reported the antimicrobial activity of six extracts 
(hydroethanolic and acetone extracts of M. charantia leaves, fruits 
and seeds) obtained from the northeastern region of Brazil in order to 
justify its popular use, in addition to conducting phytochemical profile 
of the most promising extracts.
MATERIALS AND METHODS
Chemicals and reagents
Brain heart infusion media and Agar Sabouraud Dextrose (Kasvi), 
Müller-Hinton agar, methanol, trichloroacetic acid, ascorbic acid, 
potassium phosphate buffer, acetonitrile, ethanol, and methanol, used 
were hypergrade for LC-MS LiChrosolv® and are products of MerkKGaA, 
Germany. Others such as formic acid 98-100% and n-Hexane were also 
purchased from MerkKGaA, Germany. Dimethylsulfoxide (Biology 
applications grade, Sigma-Aldrich, Inc), Oxacilin and fluconazol 
(Sigma Chemical Company, St. Louis, MO, USA.
Botanical material
The plant was collected from the Medicinal Plants Garden of Prof. 
Francisco José de Abreu Matos, Universidade Federal do Ceará, in the 
flowering and fruiting period, precisely in June 2018. The herbarium 
specimens’ were deposited in the Herbarium Prisco Bezerra the 
Universidade Federal do Ceará with specimen voucher number 
EAC31609 and identified as Momordica charantia L. For the preparation 
of the extracts, the leaves, fruits and seeds were submitted to drying in 
an air circulating oven at 45ºC until constant weight, then milled with 
the aid of a knife mill.
Preparation of leaf, fruit pulp and seeds extracts for 
microbiological tests
Two extractions were performed for each part of the plant, with 
ethanol/H2O (7: 3) and with acetone. 0.80 g of the leaf powder, fruit 
pulp and seed were weighed separately, and placed in a test tube with 
4 mL hexane for degreasing. Subsequently, 4 mL of ethanol/H2O 
solution (7: 3) was added, homogenized and the polar compounds 
extracted in an ultrasonic bath for another 20 min with fixed power 
(135 W). The samples were then centrifuged (3000 rpm/10 minutes). 
Thehexanic phase was discarded. The hydroethanolic phase (ethanol/
H2O) was filtered on a 0.22 μm PTFE (polytetrafluoroethylene) filter, 
and thereafter the filtrate was collected in small vials, with subsequent 
drying and weighing. 
For the extraction with acetone, the same procedure was performed, 
except that before adding acetone the hexanic phase was removed.
Thus, six extracts were obtained and coded as follows: Leaves - 
hydroethanolic extract/ethanol/H2O (LHE) and acetone extract 
(LAE); Fruits - ethanol/H2O extract (FHE) and acetone extract (FAE); 
Seeds- ethanol/H2O extract (SHE) and acetone extract (SAE). All these 
samples were dried and weighed to calculate their yields.
To evaluate the antimicrobial action, the extracts were dissolved in 1% 
dimethyl sulfoxide solution (DMSO, Merck).
Microorganisms
All bacterial and fungal strains used in in vitro experimental models 
were obtained from the collection of the reference microorganisms used 
in Sanitary Surveillance (CMRVS, FIOCRUZ-INCQS, Rio de Janeiro) 
and were maintaned in the Applied Microbiology Research Laboratory 
of Universidade Federal do Ceará. These are Staphylococcus aureus 
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ATCC 14458 (oxacillin sensitive), S. aureus CCBH 5330 (oxacillin 
resistant and methicillin resistant strain MRSA), Staphylococcus 
epidermidis ATCC 35984, Pseudomona aeruginosa ATCC 9027 and 
Candida albicans ATCC 10231. 
To prepare the microbial inoculum, the strains were cultured in Brain 
Heart Infusion (BHI) broth for bacteria or Sabouraud broth for yeasts. 
Subcultures were incubated for 24 hours at 37 °C. For standardization of 
the inocula, aliquots taken from the subcultured tube were transferred 
to 0.85% sterile saline to otained turbidity equivalent to the McFarland 
0.5 scale (about 108 CFU/mL or 106 CFU/mL for bacteria and yeast, 
respectively). This suspension was diluted to obtain the final microbial 
colony forming units (CFU) of 106 CFU/mL for bacteria or 104 CFU/
mL for yeasts, and which were used in all the microbiological assays.
The determination of the Minimum Inhibitory Concentration (MIC) 
was performed according to the methodology recommended by the 
Clinical and Laboratory Standard Institute.31,32 In the 96-well, sterile 
microplates, 100 μL of culture medium (BHI broth for bacteria or 
Sabouraud for yeast), 20 μL of the sample (extract), were added in 
serial concentrations ranging from 2000.0 to 31.2 μg/mL and 80 μL 
of the microbial suspensions (106 and 104 CFU/mL, for bacteria and 
yeast, respectively). Controls of turbidity, medium sterility, microbial 
growth, diluent sterility and inhibition by the diluent were performed. 
As positive controls, oxacillin and fluconazole were used for bacteria 
and yeasts, respectively, at concentrations ranging from 0.0488 to 100 
μg/mL.
The microplates were incubated for 24 hours at 37 °C and after this 
period, the visual reading of bacterial growth was carried out. MIC 
was determined as the lowest concentration of test substance capable 
of inhibiting microbial growth to the naked eye, as evidenced by the 
absence of turbidity.31,32
For extracts with intense turbidity, 10 μL of resazurin (0.01%) was 
added and incubated at 37 °C for 2 hours. The maintenance of the 
blue color in the wells was interpreted as absence of bacterial growth, 
and the development of pink color, as occurrence of bacterial growth. 
The MIC was defined as the lowest concentration of the test substance 
in which there was no change in coloration.33 The experiments were 
performed in triplicate and at two different times.
For determination of Minimum Bactericidal Concentration (MBC), 5 
μL aliquots of microplate wells used to determine MIC that did not show 
bacterial growth were seeded in Petri dishes containing plate count agar 
and incubated for 24 hours at 37 °C. After this period, colonies were 
counted. MBC was considered as the lowest concentration capable of 
inhibiting bacterial growth by at least 99.9% of the initial inoculum.34,35
Analysis by ultra-performance liquid chromatography-
quadrupole time-of-flight mass spectrometry (UPLC-QTOF-ESI-
MS)
Phytochemical analysis was performed only on extracts that presented 
significant antimicrobial activity. The extracts were prepared as 
described in Section 2.2 for UPLC analysis. After filtration in 0.22 μm 
PTFE filters, each extract was withdrawn and 100 μL of the standard 
internal solution (anthracene-9-carboxylic acid) was added at a 
concentration of 10 μg/mL (10 ppm). Only LHE and LAE extracts were 
subjected to UHPLC analysis. 
The analysis was performed in Acquity UPLC system (Waters), coupled 
to a Quadrupole / Flight Time (QToF, Waters) system. Chromatographic 
runs were performed on a Waters Acquity UPLC BEH column (150 
x 2.1 mm, 1.7 um), fixed temperature of 40 °C, mobile water phases 
with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid (B), 
gradient ranging from 2% to 95% (15 min), flow rate of 0.4 mL/min and 
injection volume of 5 μL. High-resolution mass conditions - XEVO-
QToF. The ESI-mode was acquired in the range of 110-1180 Da, fixed 
source temperature at 120 ᵒC, desolvation temperature 350 RegularC, 
withdrawal gas flow of 500 L/h, extraction cone of 0.5 V, capillary 
voltage of 2.6 kV. ESI + mode was acquired in the range of 110-1180 
Da, source temperature 120 fixed RegularC, desolvation temperature 
350 0C, desolvation gas flow 500 L/h and the capillary voltage of 3.2 kV. 
Leucine encephalin was used as a lock mass. The acquisition mode was 
MSE. The instrument was controlled by Masslynx 4.1 software (Waters 
Corporation).
The software used for data processing was the Masslynx (Waters 
Corporation) where the molecular formulas were calculated with their 
respective masses. The identification of the compounds was made based 
on comparison of spectral patterns already discussed in the literature 
regarding the species of M. charantia. In addition, online databases 
containing information on characterized metabolites such as Scifinder, 
Knapsack, PubChem and Chemspider were also consulted. 
RESULTS AND DISCUSSION 
Extracts yields
The yields of the six extracts, previously encoded, were as follows: 
LHE 9.8%, LAE 4.2%, FHE 17%, FAE 5.2%, SHE 13% and SAE 5.4%. 
Microbiological assays
The only extracts that presented significant antimicrobial activity 
were those of the leaves, which are LHE and LAE, and therefore data 
for extracts without activity were not shown in the Table 1. 
In the present study, antimicrobial activity of LHE and LAE was 
detected against four of the five clinically important bacterial and 
fungal isolates. The highest effect was observed for the acetone extract 
(LAE) (Table 1). 
According to Aligiannis et al.36, MIC values <0.5 mg/mL are considered 
potent inhibitors; MICs between 0.6 and 1.5 mg/mL are moderate 
inhibitors; and MIC> 1.6 mg/mL are weak inhibitors. Thus, the LAE 
extract is a potent inhibitor on strains of S. aureus, moderate on S. 
epidermidis and weak on yeasts (C. albicans). The antibacterial activities 
of extracts and fractions prepared from different parts of M. charantia 
have been reported from various parts of the world.28-30,37,38 The parts 
with reports of antimicrobial activities include the fruits, seeds, leaves 
and the stems. However, it is interesting to note that comparison based 
on literature reports is difficult based on many reasons. Sometimes, 
the minimal concentrations employed are in excess of up to 10 times 
the maximum concentration that we employed or even difficult to 
deduce37,38, in some others the concentrations were not stated, but 
rather the activity stated38,39 and there seems not to be any clear criteria 
for reporting plants’ extracts antimicrobial activities in many cases.37,39 
in addition, the solvents or the methods employed are completely 
different.37,39,40
On this basis, true comparison of the activities reported on M. 
charantia from different parts of the world seem to be a daunting and a 
very difficult task. In the case of divergent in the activities reported for 
the plants with similar methods used, the differences in the activities 
reported can be due to one of or combination of the following reasons: 
variations in the seasons of collections, temperature, water availability, 
ultraviolet radiation, nutrients availability, atmospheric pollution, 
mechanical damage, and pathogen attacks.41These external differences 
invariably influence the composition and levels of important secondary 
metabolites of the plant materials employed in these different studies, in 
addition to the variations related to methodological approaches in the 
antimicrobial assays.42
LHE extract, on the other hand, is a potent inhibitor of S. aureus 
strains, but moderate on S. epidermidis. The differences observed in the 
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antimicrobial potential between LAE and LHE extracts on strains of 
Staphylococcus may be due to the differences in metabolites composition 
of both extracts. Some cucurbitacins have been shown to have in vitro 
antibacterial activities.43-46 An excellent review on cucurbitacins and its 
derivatives was made by Jian et al.47 Interested reader would find the 
review interesting. 
Identification of chemical constituents of the 
hydroethanolic and acetone extracts (LHE and LAE)
The major chemical constituents of M. charantia leaves are the 
tetracyclic triterpenoids and their glycosides, most of which are 
referred to as cucurbitans, and are known for their bitterness and 
biological effects, in addition to quercetins and kaempferols. 
The cucurbitacins belong to a class of plant triterpenic, tetracyclic 
compounds and highly oxygenated derivatives cucurbitane skeleton. 
Cucurbitane-like molecules have several polarities due to the 
variation of substitutions in the side chain or portions of glucose or 
rhamnose47-56. Several compounds were isolated from extracts of M. 
charantia by separations involving chromatographic processes, which 
served as reference in the identification of the chemical constituents of 
the present study.
The chromatograms of the hydroethanolic (LHE) and acetone (LAE) 
extracts obtained in the positive ionization mode are shown in Figures 
3A and B, respectively. The characterized compounds are summarized 
in Table 2 with the relevant data, including retention time, experimental 
mass and calculated m/z, molecular formula, error in ppm provided by 
the software and the MS/MS fragments. Chemical profile of the extracts 
afforded the tentatively identification of 14 compounds. These are one 
amino acid, four flavonoids and nine triterpenoids derivatives. 
A brief comparison between the hydroethanolic extract and acetone 
extract of the leaves of M. charantia revealed some striking differences. 
Tryptophan, quercetin and kaempferol hexoside were found only in the 
LHE extract, while LAE extract presented two unknown compounds, 
Table 2. 
Tryptophan was identified by the precursor ion at m/z 205 
(C11H13N2O2) and the characteristic fragment at m/z 130 (indol 
nucleus).57 Quercetin-O-hexoside isomers showed a precursor ion 
at m/z 465 (C21H21O12) and a product ions at m/z 303, key fragment 
of quercetin aglycone, resulted from the loss of glucose unit. 
Additionally, quercetin-O-rhamnoside shows a typical precursor 
ion m/z 449 (C21H21O11) and the characteristic fragment at m/z 303, 
loss of rhamnose.64 Kaempferol-O-hexoside showed an m/z at 449 
(C21H21O11), with a key fragment of the kaempferol nucleus at m/z 287 
indicated by the loss of a hexose. Prior studies have identified these 
compounds in M. charantia.58,65,66
Curburbitane-type triterpenes were identified due the losses of H2O 
(18 Da), CO (28 Da) as well as because of a diagnostic fragment 
ion at m/z 109 resulting from the break of C17-20 linkage. Thus, 
hydroxycucurbitatetraenal isomers were identified by the precursor 
ion at m/z 437 (C30H45O2) and its product ions at m/z 419, 409, 391, 
109. An example of this fragmentation pattern occurs with the 
3β-hydroxycucurbita-5 (10), 6,22 (E), 24-tetraen-19-al, Figure 4, as 
previously reported in M. charantia.59-63,67 Epoxy isomers showed 
an additional oxygen (16 Da) and same fragmentation pattern. The 
Figure 5 depicts the MS fragmentation to 5β,19-epoxycurcubita-
6,22(E),24-triene-3β,19-diol59,61, and 3-[(5-formyl-7β,25-
dihydroxymethoxycucurbita-5,23-dien-3-yl)oxy]-3-oxopropanoic 
acid62, Figure 6.
Figure 3: Chromatograms of the UPLC-ESI-QTof MS extracts, LHE (A) and LAE (B), of M. charantia obtained in positive 
ionization mode. Peaks with “X” are impurities.
Microorganism Leaves extracts
LHE
MIC
LAE
MIC MBC
S. aureus ATCC 14458 0.5 0.25 -
S. aureus CCBH 5330 - 0.125 2.0
S. epidermidis ATCC 35984 2.0 1.0 -
P. aeruginosa ATCC 9027 - - -
C. albicans ATCC 10231 - 2.0 2.0
Table 1: Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC), in mg/mL, of EtOH/
H2O and acetone extracts of M. charantia.
LHE: leaves hydroethanolic extract (ethanol/H2O, 7:3); LAE: acetone extract.
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Peak Rt
min
[M+H]+/ 
[M+Na]+
Observed
[M+H]+/ 
[M+Na]+
Calculated
Product 
Ions (MS/MS)
Empirical
Formula
Ppm 
(error)
Putative Name LHE  LAE Ref
1 4.17 205.0974 205.0977 146.0581, 130.0630 C11H13N2O2 -1.5 Tryptophan x - 57
2 4.35 465.1047 465.1033 303.0482 C21H21O12 3.0 Quercetin-O-hexoside x - 58
3 4.49 465.1031 465.1033 303.0475 C21H21O12 -0.4 Quercetin-O-hexoside x x 58
4 4.52 449.1071 449.1084 303.0463 C21H21O11 -2.9 Quercetin-O-rhamnoside x x 58
5 4.60 449.1101 449.1084 287.0553 C21H21O11 3.8 Kaempferol-O-hexoside x x 58
6 4.93 805.5035 805.5043 787.4910, 614.4079, 175.1103 C52H69O7 -1.0 Unknown x - -
7 5.03 769.4990 769.4985 333.1419, 175.1169 C56H65O2 0.6 Unknown x - -
8 5.84 437.3416 437.3420 419.3302, 409.3449, 391.3350, 109.0965 C30H45O2 0.9
Hydroxycucurbitatetraenal 
isomer x x
59
9 6.08 437.3431 437.3420 419.3287, 409.3463, 391.3387, 109.1014 C30H45O2 2.5
Hydroxycucurbitatetraenal 
isomer x x
59
10 6.27 437.3434 437.3420 419.3312, 409.3437, 391.3375, 109.1018 C30H45O2 3.2
Hydroxycucurbitatetraenal 
isomer x x
59
11 6.47 629.3694 629.3690
437.3415, 419.3294, 
409.3463, 391.3355, 
109.1007
C36H53O9 0.6
Oleanane- triterpenoid 
saponin x x
60
12 6.91 455.3530 455.3525
437.3390, 419.3274, 
409.3472, 391.3347, 
109.1015
C30H47O3 1.1
Epoxycurcubitatrienediol 
isomer x x
22,61
13 7.26 581.3455 581.3454
541.3593, 523.3412, 
495.3454, 437.3396, 
409.3545, 391.3342, 
109.0979
C33H50O7Na 0.3
3-[(5-formyl-7β,25-dihy-
droxymethoxycucurbita-5,-
23-dien-3-yl)oxy]-3-oxopro-
panoic acid isomer
x x 62
14 7.52 455.3527 455.3525
437.3463, 419.3361, 
409.3446, 391.3396, 
109.1000
C30H47O3 0.4
Epoxycurcubitatrienediol 
isomer x x
59,63
15 9.57 477.3376 477.3376 437.3398, 419.3287, 391.3346, 109.0984 C32H45O3 1.5 Unknown x x -
16 9.76 525.3571 525.3580
493.3336, 437.3434, 
419.3293, 391.3380, 
109.1009
C33H49O5 -1.7 Unknown x x -
Table 2: Chemical identification of compounds of the hydroalcholic (FEC) and acetone (FAC) extracts from the leaves of  L. “Melão-
de-são-caetano”.
OHC
HO
OHC
O
H
H
OHC
H2O
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1
0
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0
0
9
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3
4
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4
1
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3
3
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3
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O
H
H
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H2O
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4
0
0
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9
.
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Literature survey of ethnomedicinal uses and biological 
or pharmacological compounds identified or isolated 
from M. charantia. 
We present the ethnomedicinal uses reported from the northeastern 
region of Brazil (Table 3) and then made a summary of phytochemicals 
reportedly identified or isolated from M. charantia and verified in this 
present local variety, with the view of presenting plausible role for 
these metabolites in the potential therapeutic effects of this plant. 
Literature survey of the ethnomedicinal uses in the northeast region 
of Brazil of M. charantia and its identified metabolites revealed some 
interesting findings. In spite of the widespread uses of this important 
food and medicinal plants, there are still lack of rigorous preclinical 
and clinical studies, particularly for many of its ethnomedicinal claims. 
In fact, there is no clinically supported medicinal uses.68 It is also 
surprising that some of the biological activities reported are anecdotal 
due to poor experimental designs, among others. For example, some 
studies related its biological activities using solutions made from the 
plants parts without stating the concentrations or dose used, the use 
of solvents other than those used reported in the ethnomedicinal uses, 
the parts used in the studies and sometimes the route of administration 
of the extracts. The most pre-clinically substantiated activities of M. 
charantia are its anti-diabetic and anti-neoplastic activities16,20,26,27,69,70.
In the present study, we demonstrated the antibacterial and antifungal 
activities of the leaves extracts of M. charantia against clinically 
important bacterial and fungal strains. Similar reports have been 
observed in the literature28-30,37,106. In order to be able to give plausible 
explanation as to the activity observed as well as to standardized the 
extracts, we performed phytochemical studies on the two extracts 
studied in the present work. Among the structures identified by UPLC 
in LHE and LAE extracts of M. charantia, a number of compounds 
derived from flavonoids and many of which have been shown to possess 
antimicrobial activities were identified in LHE. However, some of these 
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constituents do not appear in LAE extract, which presented better 
antimicrobial and antifungal activity, suggesting that there are other 
metabolites, that were not identified in the present work and, which 
may contribute, at least in part, to the antibacterial and antifungal 
activities observed. 
To the best of our knowledge, there are no sufficient chemical and 
biological studies to indicate the substances responsible for antibacterial 
or antifungal activity of M. charantia.
These results further demonstrate therapeutic potential of M. 
charantia extracts and calls for further biological and pharmacological 
prospecting of this important plant. There is need for in vivo 
antimicrobial assays to confirm the potential antimicrobial activity of 
the plant and its phytochemical constituents that are yet to be subjected 
to biological/pharmacological studies. In fact, most of its important 
phytochemical compounds are without biological or pharmacological 
studies. Majority of studies on its isolates are focused on antidiabetic 
and anti-cancer activities. In addition, there is lack of studies on 
many of its ethnomedicinal uses. Furthermore, there is need to carry 
out mechanistic studies to determine how M. charantia and or its 
constituents afford the antimicrobial action observed here as in many 
studies. 
CONCLUSION
The hydroethanolic extract (LHE) and acetone (LAE) from M. 
charantia L. showed different patterns of antimicrobial action against 
Gram-positive bacteria (S. aureus and S. epidermidis) and on yeast 
(C. albicans), which are believed to be due to the differences in the 
composition of extracts as shown by the UPLC analysis of constituents. 
The study is a pioneer in the association between antimicrobial activity 
of different Brazilian bitter gourd extracts and its chemical constituents. 
Nevertheless, studies that will evaluate the compounds alone and in 
association, as well as those investigating their mechanisms of action 
are needed to elucidate this pharmacological effect. 
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Ethnomedicinal uses Confirmed biological/ pharmacological activities
Chemical compounds or extracts 
with activity References
Indication in skin treatments wound 
healing. Wound healing: various model Fruit powder, extracts
26,71–77
Antiseptic (skin infections, mycoses) 
and antimicrobial Antibacterial and antifungal activities
Quercetin-O-hexoside isomers, 
kaempferol, tannins, flavonoids and 
alkaloids, various crude extracts 
29,78–90
Antiviral antiviral activity (inhibit HRV2 replication) Quercetin-7-Glucoside
91,92
Scabies, vermifuge, anthelminthic Anti-helminthic activity Crude extracts 93
Tumor and benign breast neoplasm
Antineoplastic and anti-tumor, 
anti-hepatocellular carcinoma; renal 
carcinoma cells in-vitro anticancer, 
malignant melanoma, cytotoxicity 
against chondrosarcoma SW 1353 
cell line; modulates the progression of 
androgen-independent human prostate 
cancer cell line.
MAP30,  Cucurbitacins (Cucurbitacin E 
glucoside, and Cucurbitacin I glucoside, 
cucurbitacines A, B, D, E), Kuguacin 
J and Cucurbitane-type triterpenoids 
(charantosides, momordicosides, 
karavilosides, karavilagenin D) and 
quercetin
19,20,26,27,45,47,49–54,56,70,94–105
Anti-diabetic 
Antidiabetic activity, stimulatory effect 
on insulin secretion and various others, 
including clinical trials(too numerous 
to mention all)
Different extracts of M. charantia, 
Kuguacin (The Kuguacin R and 
Kuguacin II, 3β,7β,25-trihydroxycucur 
bita-5,23(E)-diene-19-al, momordicine 
I, Momordicosides L, charantoside VII 
15,17,26,27,61,69,106–108
Table 3: Summary of ethnomedicinal uses, chemical compounds identified, and activities reported in the literature that corresponds to M. charantia 
ethnomedicinal uses in the northeastern region of Brazil.
Internal and external inflammation
Pre-clinical anti-inflammatory 
activities, and in patients with primary 
knee osteoarthritis
Cucurbitacins, quercetin, kaempferol,  
and plant crude extracts
17,20,71,105,109–119
Contraceptive Antiestrogen activity
Triterpenoid, Kaempferol Cucurbita-6, 
22 (E), 24-trien-3β-ol-19,5β-olide, 
crude extract
59,120
Immunostimulanting Immunomodulatory activity Polysaccharides from M. charantia 121
Antimalarial In vitro (positive) and in vivo (no effect) anti-plasmodium activity Crude extracts
122,123
Anti-diarrheal In vivo anti-diarrheal activity Crude aqueous extract 124
Indication in skin treatments: eczema, 
acne, scabies, hemorrhoid, and 
furuncles, carbuncle
No report No report
Gastroenteritis No reports No reports
Colitis No reports No reports
Gynecological inflammation No report No report
Vaginal discharge No report No report
Hemostatic No reports No reports
Nasal congestion No reports No reports
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